Brookline Capital Management Predicts Moderna FY2029 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Equities researchers at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for Moderna in a research report issued on Monday, January 13th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $22.02 for the year. The consensus estimate for Moderna’s current full-year earnings is ($9.30) per share.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. Moderna’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.39) EPS.

A number of other research analysts have also issued reports on MRNA. Berenberg Bank upped their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday. Jefferies Financial Group cut their price target on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Wolfe Research began coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective on the stock. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Finally, Barclays decreased their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a report on Friday, November 8th. Four investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $75.58.

Moderna Stock Down 2.9 %

Shares of NASDAQ:MRNA opened at $33.76 on Wednesday. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $12.99 billion, a P/E ratio of -5.80 and a beta of 1.60. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47. The stock’s fifty day simple moving average is $41.11 and its 200-day simple moving average is $67.32.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold 2,664 shares of company stock valued at $115,210 in the last quarter. Company insiders own 15.20% of the company’s stock.

Institutional Trading of Moderna

Several large investors have recently added to or reduced their stakes in MRNA. State Street Corp raised its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC raised its holdings in Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Moderna by 21.0% in the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after buying an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Moderna by 6.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after acquiring an additional 178,939 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.